Image Credit: Health and me
There's been an alarming increase of respiratory and gastrointestinal viruses in the United States lately, causing anxiety about a so-called "quad-demic". According to surveillance reports, influenza, COVID-19, RSV and norovirus are at very high levels everywhere. While the surge aligns with patterns typical for this season, several epidemiologists view simultaneous infections of such proportions to pose risks not only to individual healthcare but public health.
The incidence of the quad-demic should vary with seasonal patterns, vaccination rates, and public health interventions. Each virus alone is relatively easy to manage; however, the effect of all together could lead to overburdening of health care facilities and increase risks for those at higher risk. Continuing surveillance, early testing, and proactive prevention measures will play an important role in the control of these infections going forward.
While the term "quad-demic" sounds daunting, it must be taken into perspective. For years, we have had all these viruses together, and we have the capabilities to mitigate some of the risk. Vaccination, proper hygiene and using common sense helps individuals get through the season unscathed. Is the quad-demic a permanent fixture or just another seasonal wave? Let's break this down.
Typically, flu, COVID-19, and RSV have been the primary culprits behind seasonal respiratory infections. However, norovirus, a highly contagious stomach bug, has emerged as a fourth significant player, inducing fears of a more severe and widespread viral outbreak. According to the Centers for Disease Control and Prevention (CDC), the U.S. recorded nearly 500 norovirus outbreaks between August and December 2023, a substantial rise from the previous year’s numbers.
While the term "quad-demic" may sound ominous, the seriousness and consequences of such infections should be weighed in light of the U.S. healthcare system's experience with managing viral surges since the start of the COVID-19 pandemic.
Flu continues to be one of the most common and alarming seasonal illnesses. In the period spanning from 2023 to 2024, there were approximately 40 million cases of flu, and thousands of hospitalizations along with reported 47 deaths have been reported this season. Flu symptoms include fever, chills, cough, sore throat, muscle pain, and fatigue, with most recovering within a week or two but risky factors for severe illness effects occur in young children, elderly, and people with chronic conditions.
Despite its reduction from the first pandemic peak, COVID-19 is still rampant. The CDC estimates that alone between October and December 2023, there were between 2.7 and 5 million cases in the U.S. Hospitalization has increased by cities such as Los Angeles, Chicago, and New York. Symptoms are closely similar to the flu, fever, cough, and fatigue but uniquely presents in some cases as loss of taste and smell.
RSV is the most common cause of lower respiratory infections in infants, older adults, and immunocompromised individuals. While RSV peaked late in 2023 and early 2024, it continues to be a threat because it can lead to bronchiolitis and pneumonia. It is very similar to the common cold, presenting with symptoms such as congestion, runny nose, coughing, and fever, which can make it difficult to differentiate from flu or COVID-19 without testing.
Norovirus, also called the "stomach flu," is a highly contagious infection of the gastrointestinal tract, not a respiratory virus. It transmits quickly from contaminated food and water and contact with contaminated surfaces, causing such symptoms as diarrhea, vomiting, nausea, and stomach pain. Cases have shot up, the CDC said Monday, with reports of outbreaks surging compared with last year.
The greatest challenge during the quad-demic is how the four viruses are alike and thus make identification very hard with no testing applied. Most cases present symptoms common to all viruses: fever, tiredness, body pains, and respiratory, which includes coughing and congestions for influenza, COVID-19, and RSV; the other would be norovirus symptoms as nausea and vomiting can appear even in extreme influenza and COVID-19. This overlap increases the risk of misdiagnosis and delayed treatment, hence the need for early testing and proper medical guidance.
Also Read: Is US Preparing For A Quad- demic 2025?
The best defense against these viruses is a combination of vaccines, hygiene, and lifestyle precautions. While lifestyle modifications are highlighted as part of the constant need to eat healthy, ensure daily movement and drinking adequate amount of fluids. There is a sure short two preventive strategies that are effective:
While debates on masked wear continue on, experts on mask-wear affirm that this does not only have a historical precedent but works towards reducing airborne viruses spreading within the environments. Hospitals, though, ensure masking in key sections of themselves. Publicized mask-wear remains a discretion, though massing indoors still goes a longer way in cases like peak flu seasons.
If you notice the symptoms of these viruses, then it's best to be confined at home and avoid having face-to-face interaction with others and seek immediate attention from your physician if your condition worsens. Quarantining for some days can decrease the spread of infection.
As we move into the first half of 2025 and beyond, staying informed and proactive is the best strategy for maintaining health and avoiding unnecessary panic. The key takeaway? Stay vigilant, but don’t be alarmed—these viruses are here, but so are the means to fight them.
Credits: PTI
Delhi woke up to a slightly lower levels of AQI on Sunday Morning, November 30, as city's AQI dropped to 269 at 7am down from 305, which was recorded at 4pm on Saturday. This now falls under the "poor" category. However, experts say that the relief is temporary.
Many health experts and those who have studied the impact of pollution on humans have pointed out that anything above 300 is harmful to humans. These harms are not just limited to respiratory illnesses, and to lungs, causing lung cancers, but can also be the reason why obesity is on the rise.
As per a 2021 study titled Effect of Air Pollution on Obesity in Children: A systematic Review and Meta-Analysis, there is a connection between air pollution and weight gain through biological behavioral mechanism. The major pollutants causing obesity are nitrous oxides, nitrogen dioxide, ozone, and particulate matter.
These could lead to systematic inflammation and metabolic disturbances, which can lead to weight gain and obesity. The study mentions that fine particulate matter [PM2.5], when it enters our body, it influences the metabolism rates.
The 2021 study also revealed that increase in air pollution, and road traffic noise was also associated with childhood obesity.
Also Read: 'Facing Breathing Issues After Morning Walk' Says CJI Surya Kant As Delhi's Toxic Air Worsens
Another 2011 study titled The influence of air pollution on cardiovascular and pulmonary function and exercise capacity: Canadian Health Measures Survey (CHMS), found that air pollutants may indirectly impact body weight by raising the risk of chronic conditions like blood pressure, heart diseases or lung diseases. "Exposure to higher concentrations of air pollution was associated with higher resting blood pressure and lower ventilatory function. Ozone was associated with reduced exercise capacity," researchers of the study wrote.
The latest study published in 2024 titled The association between air pollution and obesity: an umbrella review of meta-analyses and systematic reviews, found that air pollution can impact metabolic function by influencing inflammation in fat tissue. It leads to an increase in oxidative stress and alters one's dietary habits.
This does not end here, air pollution could also negatively impact women. As Dr Anuradha Kapur, Principal Director (Obstetrics & Gynaecology) and Head of Unit, Max Smart Super Speciality Hospital, Saket says, "Environmental pollutants, such as pesticides and microplastics, can affect reproductive health and hormone regulation, potentially impacting menstrual cycles."
Dr Sonam Simpatwar, Gynaecologist with a diploma in reproductive medicine, practising at Central Railway Hospital, Mumbai further explained how pollutants impact women's health:
Endocrine Disruptors: Chemicals found in pollution, plastics, and pesticides can mimic or interfere with hormones, potentially affecting menstrual cycles.
Climate Change: Rising temperatures, extreme weather events, and changes in water quality can impact food production, nutrition, and overall health, which can indirectly affect menstrual health.
Stress: Environmental stressors, such as pollution and climate change, can lead to increased stress, which is known to influence menstrual cycles.
"It's important to note that these are potential factors, and more research is needed to fully understand their impact on menstrual health," she said.
Credits: Canva
High levels of low-density lipoprotein cholesterol (LDL-C), commonly called "bad" cholesterol, continue to be a leading modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD) worldwide. While statins and other cholesterol-lowering medications have significantly improved treatment, many patients still do not reach the LDL-C targets recommended by guidelines.
However, a new potential solution has emerged. The experimental daily oral drug called enlicitide, part of the PCSK9 inhibitor class, demonstrated in a key Phase 3 study (CORALreef Lipids) a reduction in LDL-C of about 55.8% at 24 weeks, with post-hoc analysis suggesting reductions up to 59.7% compared to a placebo.
Statins are the standard first-line treatment for high LDL-C and have strong evidence for lowering the risk of cardiovascular events. Yet, many patients either cannot tolerate high doses or still have elevated cholesterol levels. Injectable PCSK9 inhibitors, which are monoclonal antibodies, address this gap and can lower LDL-C by up to 70% but are expensive, require injections, and have limited uptake.
Introducing an oral PCSK9 inhibitor could make powerful LDL-C reduction more accessible. According to trial data, enlicitide may achieve reductions similar to injectable options while being more convenient and potentially more widely available.
The CORALreef Lipids Phase 3 study involved 2,912 adults at risk of or with established ASCVD who were either already on lipid-lowering therapy or unable to take statins. Participants were randomly assigned to receive a daily 20 mg dose of oral enlicitide or a placebo. At 24 weeks, the main analysis showed an average LDL-C reduction of 55.8%, with a post-hoc reanalysis estimating 59.7%. The drug’s safety profile was similar to placebo, with no major safety concerns reported and low rates of discontinuation due to adverse effects.
These reductions are substantial, suggesting oral enlicitide could:
In India, where ASCVD prevalence is high and expensive therapies are less accessible, this pill could provide a practical, scalable option alongside diet, exercise, and current statin or ezetimibe treatments.
Despite the promising LDL-C reductions, several key issues remain:
The investigational oral pill enlicitide could represent a major advance in cholesterol management. For patients whose LDL-C remains high despite statins, or who cannot tolerate injections, it offers a potent and convenient alternative. Yet, medicine requires caution.
Disclaimer: This content is for general informational purposes only and is not a substitute for professional medical advice. Always consult a doctor or specialist before starting or changing any medication
Credits: Canva
According to NHS advice, people who use gabapentin may face rare emergencies linked to the medicine. Although it is not officially classed as a painkiller, doctors often prescribe it for nerve pain that follows an injury. It is also used for discomfort caused by shingles or diabetes. The medicine works by interrupting pain signals that move between the brain and spinal cord. Gabapentin is also a common treatment for epilepsy and falls under the group of anticonvulsant drugs. Most people take it as capsules, tablets, or a liquid, usually three times a day.
NHS information notes that the majority of users do not face any side effects. Those who do usually notice only mild and short-lived symptoms.
Gabapentin is a prescription drug that belongs to a group of medicines called anticonvulsants. Doctors usually give it to people who have nerve pain or to help manage certain types of seizures in epilepsy. It is sold under names like Neurontin, Gralise, and Horizant, along with widely used generic versions.
Gabapentin is prescribed for a few main purposes:
There are times when gabapentin may lead to serious reactions that need emergency attention. Mild effects can include an upset stomach, dry mouth, weight gain, or slight memory troubles.
More concerning reactions may involve thoughts of self-harm, unusual muscle pain or weakness, or seeing or hearing things that are not there. Even then, NHS guidance states that these usually require an urgent call to a doctor or 111 rather than ambulance help.
Like many medicines, gabapentin can trigger a severe allergic reaction known as anaphylaxis. This can cause several symptoms, such as swelling in the throat or difficulty breathing. The NHS advises calling 999 if you are taking gabapentin and experience any of the following:
© 2024 Bennett, Coleman & Company Limited